Marfan syndrome: Difference between revisions

No edit summary
Line 1: Line 1:
==Background==
==Background==
*Hereditary [[connective tissue disorder]]
*Marfan syndrome (MFS) is a heritable [[connective tissue disorder]] with multi-system involvement
**Caused by autosomal-dominant mutation in fibrillin gene (FBN1)
**First described by Antoine Marfan in 1896
**75% of cases are autosomal dominant with different features among family members
**Clinical features vary along a spectrum typical of autosomal-dominant disorders
**25% mutations occur spontaneously, though may be associated with older paternal age
 
*Autosomal-dominant mutation in FBN1 gene (encoding fibrillin-1) on chromosome 15
**This results in cystic medial degeneration of the aortic tunica media (leading to increased risk of aortic aneurysm / dissection)
**This also interferes with elastin deposition during extracellular matrix formation implicates in the elasticity of multiple tissue types
**Majority of cases (75%) are familial / inherited vs. minority (25%) are de novo mutations
 
*Estimated prevalence of 1/5000 individuals worldwide (equal between men and women)
 
*Life expectancy for those diagnosed and treated is now close to that of non-MFS population (previously expected increase in patient mortality by third and fourth decades of life)


==Clinical Features==
==Clinical Features==

Revision as of 15:13, 13 August 2025

Background

  • Marfan syndrome (MFS) is a heritable connective tissue disorder with multi-system involvement
    • First described by Antoine Marfan in 1896
    • Clinical features vary along a spectrum typical of autosomal-dominant disorders
  • Autosomal-dominant mutation in FBN1 gene (encoding fibrillin-1) on chromosome 15
    • This results in cystic medial degeneration of the aortic tunica media (leading to increased risk of aortic aneurysm / dissection)
    • This also interferes with elastin deposition during extracellular matrix formation implicates in the elasticity of multiple tissue types
    • Majority of cases (75%) are familial / inherited vs. minority (25%) are de novo mutations
  • Estimated prevalence of 1/5000 individuals worldwide (equal between men and women)
  • Life expectancy for those diagnosed and treated is now close to that of non-MFS population (previously expected increase in patient mortality by third and fourth decades of life)

Clinical Features

Increased risk of: